Eli Lil­ly has an­ted up for its next big bet on a next-gen pain drug, buy­ing Hy­dra as­sets

With its new CGRP mi­graine drug Em­gal­i­ty (gal­canezum­ab) OK’d a few months ago and more late-stage work un­der­way on las­mid­i­tan and tanezum­ab, Eli Lil­ly’s pain group has se­lect­ed its next shot at a next-gen drug. 

The tar­get is TR­PA-1, one of the fam­i­ly of ion chan­nel tar­gets that has long been a fo­cus at Hy­dra Bio­sciences, run by Russ Hern­don. Hy­dra at one point had a col­lab­o­ra­tion on this way back in 2012 with Cu­bist, just be­fore Cu­bist got bought out by Mer­ck.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.